A drug that didn't meet expectations in a trial is to blame.

We sat down with CEO Brett Monia to talk through 2026 and beyond -- and why Ionis is thinking well past its near-term ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027.

- Positive data from a Phase 2 study of IONIS-FB-L Rx support further development for treatment of patients with IgA nephropathy CARLSBAD, Calif., July 11, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, ...

CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license ...

Ionis is a promising biotech with a strong late-stage pipeline and lucrative Big Pharma partnerships, despite current weak commercial revenues and heavy losses. The company has five FDA-approved drugs ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living ...

Q1 revenue rises 10% to $132 million, exceeding the $125.3 million estimate; EPS loss improves to 93 cents vs. $1.12 consensus. 2025 revenue forecast raised to $725 million–$750 million from $600 ...

On a mission to expand its recently approved Tryngolza beyond the rare genetic disorder familial chylomicronemia syndrome (FCS), Ionis recently tested its medicine in patients with moderate ...

Ionis Pharmaceuticals, Inc. (IONS), the Carlsbad, California-based, commercial-stage pharmaceutical company, announced its Q4 and full-year 2023 earnings on Wednesday after the market close. Ionis ...